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Abstract 
Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not 
well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an 
opportunity to evaluate novel treatment strategies in a personalized fashion. Here we have evaluated spatio-temporal 
functional and molecular dynamics of five PDO models established after hepatic re-resections and neoadjuvant 
combination chemotherapies in a patient with microsatellite stable and KRAS mutated metastatic rectal cancer. Histo-
pathological differentiation phenotypes of the PDOs corresponded with the liver metastases, and ex vivo drug sensi-
tivities generally reflected clinical responses and selection pressure, assessed in comparison to a reference data set of 
PDOs from metastatic colorectal cancers. PDOs from the initial versus the two recurrent metastatic settings showed 
heterogeneous cell morphologies, protein marker expression, and drug sensitivities. Exploratory analyses of a drug 
screen library of 33 investigational anticancer agents showed the strongest ex vivo sensitivity to the SMAC mimetic 
LCL161 in PDOs of recurrent disease compared to those of the initial metastasis. Functional analyses confirmed target 
inhibition and apoptosis induction in the LCL161 sensitive PDOs from the recurrent metastases. Gene expression 
analyses indicated an association between LCL161 sensitivity and tumor necrosis factor alpha signaling and RIPK1 
gene expression. In conclusion, LCL161 was identified as a possible experimental therapy of a metastatic rectal cancer 
that relapsed after hepatic resection and standard systemic treatment.
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Introduction
“Living biobanks” of patient-derived tumor organoids 
(PDOs) can model histopathological and pharmacog-
enomic heterogeneity in cancer [1–5]. Co-clinical studies 
have shown that PDOs can predict clinical responses to 
both targeted agents and chemotherapies in an obser-
vational setting [6, 7]. However, tumor heterogeneity 
is a major driving force of treatment failure [8]. PDOs 
established from distinct liver lesions of patients with 
metastatic colorectal cancer (CRC) have shown that 
inter-metastatic heterogeneity of drug sensitivities is 
limited [9], but systemic anticancer treatment inflicts 
selective pressures that can drive the evolution of drug-
resistant subclones [10–13]. Longitudinal monitoring 
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by rechallenge with anti-EGFR therapy against metastatic 
CRC guided by monitoring of  KRAS  mutation levels in 
the blood [14, 15]. However, most studies of cancer cell 
drug vulnerabilities and functional modeling are cross-
sectional and provide ’snapshots’ of a single point in time 
[1, 2, 7, 16].
Patients diagnosed with KRAS mutated CRC have 
limited systemic treatment options when resistance to 
standard combination chemotherapies with or without 
antiangiogenic agents occurs [17, 18]. The mechanisms 
of chemoresistance in KRAS-driven cancers are not 
well understood. However, acquired chemoresistance 
might be associated with evasion of apoptosis via dys-
regulated expression of inhibitor of apoptosis proteins 
(IAPs) [19, 20]. IAPs can directly inhibit caspases or 
divert death-inducing signals of the tumor necrosis fac-
tor (TNF) pathway into prosurvival signals via activation 
of the proliferative transcriptional programs of Receptor-
interacting protein kinase 1 (RIPK1) and Nuclear factor 
kappa-B (NF-κB) [19, 21–23]. Endogenous regulation of 
IAPs is mediated by second mitochondria-derived acti-
vator of caspases (SMACs), which are released from the 
mitochondria into the cytosol in response to apoptotic 
stimuli, and thus free the caspases to execute pro-apop-
totic functions. Small therapeutic compounds mimicking 
SMACs can promote apoptosis in cancers with deregu-
lated IAP expression [19]. However, the clinical success 
of SMAC mimetics as anticancer agents has been limited 
by the lack of predictive biomarkers [24].
Here, we report a longitudinal, observational co-clin-
ical study of standard combination chemotherapies in a 
patient with recurrent, KRAS mutated liver metastases 
from rectal cancer. A SMAC mimetic was identified as a 




The patient diagnosed with metastatic rectal cancer was 
surgically treated for liver metastases at Oslo University 
Hospital on three occasions, between December 2017 
and February 2020. Parallel samples from resected speci-
mens were fresh frozen (− 80  °C) for molecular profil-
ing, or transported ice-cold in basal media (Advanced 
DMEM/F-12 supplemented with 10 mM HEPES, 2 mM 
GlutaMAX all from Thermo Fischer Scientific and 
100  µg/ml Primocin from Invivogen) for organoid cell 
culturing within 24 h. A sample set of similarly processed 
liver metastases (n = 46) from 23 patients diagnosed with 
metastatic CRC described in ref [9] have been used as the 
reference dataset in this study.
Culturing patient‑derived tumor organoids
Samples from resected tumor specimens 
(2.5—6 × 7 mm in size) were minced into 0.1- 0.5 mm 
fragments, washed with ice-cold basal culture media, 
strained with a 70 µm pore mesh, and collected by cen-
trifugation at 400g 4  °C for 5  min. The pellet was sus-
pended in Growth Factor Reduced Matrigel (Corning), 
dispensed onto pre-warmed 6-well tissue culture plates 
as 25  µl drops, overlaid with 3  ml organoid growth 
media supplemented with 10  µM Y-27632 and then 
incubated at 37 °C in a humidified 5%  CO2 atmosphere. 
Organoid growth media consisted of basal culture 
media supplemented with 1xB27 supplement (Gibco), 
10 nM [Leu15]-Gastrin I (Sigma) and 1 mM N-acetyl-
l-cysteine (Sigma) and the following niche factors: 
50  ng/mL for EGF (Gibco), 100  ng/mL for Noggin 
(Preprotech), 500 nM for TGF-β receptor type I inhibi-
tor A83-01 (Tocris) and 10  µM for p38 MAP kinase 
inhibitor SB202190 (Sigma). Organoid growth media 
without Y-27632 was refreshed every two to four days. 
Organoids were passaged by digestion with TrypLE 
Express (Gibco) for 5 min at 37  °C supplemented with 
10 µM Y-27632. Contamination-free organoid cultures 
were ensured using MycoAlert Mycoplasma Detection 
Assay (Lonza) within a week after the functional assays 
or before cryopreservation. The authenticity of the 
cultures was verified by comparison to the respective 
tumor tissues using AmpFLSTR Identifiler PCR Ampli-
fication Kit (Thermo Fisher Scientific).
Drug sensitivity screening
A medium throughput drug screen of a custom library 
of 33 clinically relevant small molecule inhibitors in 
eight different concentrations each, and three drug 
combinations in seven concentrations was performed 
as previously described [9]. The drug library was 
selected for clinical relevance in CRC, and included 
all small molecules approved to treat CRC, drugs with 
emerging clinical evidence of activity against CRC, and 
selected drugs that are either approved or in clinical 
testing for other cancer types. Selection among agents 
with the same mechanism of action was based on 
robust drug sensitivity scores tested in CRC cell lines 
[25] and the furthest development in clinical studies. 
The setup of one treatment reaction included 40 fold 
drug concentration (preprinted with liquid acoustic 
dispensing technology Echo 550, Labcyte Inc. at the 
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High Throughput Biomedicine Unit at the Institute 
for Molecular Medicine Finland) overlaid with 10 µl of 
50% Matrigel, followed by a suspension of 450–600 pre-
strained organoids (70 µm mesh size) with 30 µl of 3% 
Matrigel. Two parallel replicas per sample were incu-
bated with the drugs and positive (100  µM benzetho-
nium chloride, n = 9 wells) and negative (0.1% DMSO, 
n = 13 wells) controls for 96 h at 37 °C in a humidified 
5%  CO2 atmosphere, and analyzed by the CellTiter-
Glo 3D Cell Viability Assay (Promega) according to 
the manufacturer’s instructions, prior to luminescence 
measurement with a Victor 3 microplate reader (Perkin 
Elmer). Luminescence readouts were rescaled to rela-
tive viability based on the median of the negative and 
positive control wells per plate (separately for the two 
technical replicates). Data from technical replicates 
were combined to estimate dose–response curves [9]. 
Drug sensitivity scores were calculated as described in 
Yadav et al. (2014) [26].
Growth rate adjustment of drug activities
For growth rate adjusted drug sensitivity scores (GRDSS), 
area under the curve was calculated using growth rate 
in place of relative viability based on a previously devel-
oped method for estimation of growth fold-changes [27]. 
To estimate growth rate, the following steps were per-
formed. Micrographs were captured at baseline seeding 
of each drug screen, as well as after four days of incu-
bation with the negative and positive controls using an 
EVOS FL microscope (Thermo Fisher Scientific). The vol-
ume of more than 150 structures of each sample at base-
line, and of 150 structures after 96 h incubation with the 
negative control, were measured manually using ImageJ 
(Fiji) based on the longest (l) and shortest (s) diameters of 
the structures using the following formula:
Volume fold-changes ( v ) were calculated as the mean 
volume of structures after incubation with negative con-
trol divided by the volume of the baseline structures, and 
used to calculate organoid doubling time (Td) as follows:
where Te is the experimental duration (typically 96 h).
Drug screen quality was evaluated based on the strictly 
standardized mean difference (SSMD) metric of the 
raw luminescence readouts from DMSO treated (neg) 











Samples with SSMD < 3 were discarded and repeated. 
For the included screens, the median SSMD was 9.3 
[range: 3.5–34].
DNA/RNA extractions and mutation analyses
DNA and RNA were extracted from fresh-frozen tissue 
samples and PDOs using the Allprep DNA/RNA/miRNA 
Universal kit (Qiagen GmBH, Hilden, Germany), fol-
lowing the manufacturer’s instructions. Microsatellite 
instability (MSI) status and KRAS, NRAS, BRAF hotspot 
mutation status were determined as previously described 
[9, 28].
Gene expression analyses
Gene expression profiles were generated for all resected 
liver metastasis tissue samples and their correspond-
ing PDOs using the GeneChip Human Transcriptome 
Array 2.0 (HTA 2.0) with 100  ng of total RNA as input 
and following the manufacturer’s protocol (Thermo 
Fisher Scientific). Raw intensity data were pre-processed, 
normalized and log2 transformed for tissue samples and 
PDOs separately by robust multi-array average (RMA) 
method implemented in justRMA function in the R pack-
age affy [29] using the custom Entrez CDF file (v24) from 
Brainarray [30]. Entrez IDs were converted to HGNC 
gene symbols using the org.Hs.eg.db package (v 3.7.0) 
from Bioconductor. Single-sample gene set enrichment 
analyses of gene signatures of response and resistance to 
5-fluorouracil (5-FU) [31], as well as the “hallmark” gene 
sets (n = 50; retrieved from the Molecular Signatures 
Database, v7.0 [32]) were performed by the gsva func-
tion (gene set variation analysis) in the R package GSVA 
[33]. Sensitivity to LCL161 was also analyzed in relation 
to log2 expression signals of previously suggested target 
genes encoding mediators of the TNF alpha pathway and 
apoptosis regulators [34].
Immunostaining
All PDO lines and one liver metastasis tissue were forma-
lin-fixed, paraffin-embedded and assembled in a microar-
ray with 4 mm cores, sliced at 3 µm sections, and stained 
for hematoxylin and eosin. A section was also stained and 
analyzed for caudal type homeobox 2 (CDX2), cytokera-
tin 20 (CK20), E-cadherin (ECAD) and cytokeratin 7 
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Opal kits and reagents (product numbers NEL810001KT 
and FP1495001KT, Akoya Biosciences) and multispectral 
imaging (Vectra3 imaging system, Akoya Biosciences). 
The following antibodies and fluorophores were used to 
detect each target: anti-CDX2 (1:400, clone EPR2764Y, 
Cell Marque) detected by Opal 570, anti-CK20 (1:1000, 
clone Ks20.8, Agilent Dako) detected by Opal 520, anti-
ECAD (1:10.000, clone 36, BD Biosciences) detected by 
Opal 690, anti-CK7 (1:400, clone OV-TL 12/30, Agilent 
Dako) detected by Opal 620. Cell nuclei were stained 
with DAPI. Multispectral images were unmixed in 
Inform Software (Akoya Biosciences) and all images dis-
played are scaled equally.
Western Blot analyses
7.5 ×  103 PDOs were incubated for 48  h with 200  µM 
LCL161 or 0.01% DMSO. After drug incubation, the 
cells were washed with 1xPBS, scraped, collected, lysed 
in 100 µl SDS electrophoresis sample buffer (10 mM Tris 
(pH 6.8), 15% w/v glycerol, 3% w/v SDS, 0.01% w/v brom-
phenol blue, and 5% v/v 2-mercaptoethanol), sonicated 
and heated at 95 °C for 5 min. Protein concentration was 
determined using the RC-DC Protein Assay kit (Bio-
Rad) according to the manufacturer’s recommendation. 
Protein lysates were separated on 12% SDS-PAGE gels 
by electrophoresis then blotted onto PVDF membranes 
using a Trans-Blot® Turbo™ Transfer System (Bio-Rad). 
The primary antibodies used were: c-IAP1 (D5G9) Rab-
bit mAb #7065, c-IAP2 (58C7) Rabbit mAb #3130, XIAP 
(3B6) Rabbit mAb #2045, Survivin (71G4B7) Rabbit mAb 
#2808, Cleaved Caspase-8 (Asp384) (6B6) Mouse mAb 
#9747, Caspase-7 (C7) Mouse mAb #9494, Caspase-3 
Antibody #9662, PARP Antibody Rabbit #9542, Cleaved 
PARP (Asp214) (D64E10) XP(R) Rabbit mAb #5625 all 
from Cell Signaling at 1:1000 dilution as well as anti-β-
actin #A2228 from Sigma-Aldrich at 1:5000 dilution. 
HRP conjugated secondary antibodies (Bio-Rad) were 
used at 1:5000 dilution and chemiluminescence detected 
using SuperSignal West Dura Extended Duration 
Substrate kit (Thermo Fisher Scientific) on a Bio-Rad 
image station. Protein band intensities were quantified 
with Image Lab V5.2 Software from Bio-Rad.
Results
Case presentation and PDO establishment
A 64 year old man was diagnosed with KRAS mutated 
(codon G13D), microsatellite stable rectal cancer dis-
seminated to the liver (T3N0M1; Fig.  1). The patient 
was scheduled for neoadjuvant combination chemo-
therapy with 5-FU, leucovorin and oxaliplatin (FLOX) 
followed by liver resection, and the metastases showed 
partial response (according to response evaluation cri-
teria in solid tumors 1.1) [35], with a mean shrinkage 
of the measured tumor deposits of 75% (n = 5, range: 
45%–100%) (Fig. 1 upper left). One lesion was resected 
(T1: 10 mm diameter reduction, corresponding to 55% 
tumor shrinkage; clear resection margin) and submit-
ted for organoid culturing and genomics [9]. All other 
lesions were treated with microwave ablation. His-
topathological hematoxylin and eosin stains of the 
PDOs showed three-dimensional cell structures with 
well- and poorly-defined epithelial layers and small- 
or absent lumens, indicating a moderately differenti-
ated phenotype (Fig. 1 upper right). ECAD, CDX2, and 
CK20 were expressed, whereas CK7 was absent, sup-
porting epithelial CRC tissue origin.
The patient remained disease-free until ten metasta-
ses were detected at new locations in the liver by mag-
netic resonance imaging (MRI) at follow-up 11.7 months 
after surgery. The patient was scheduled for chemother-
apy followed by hepatic re-resection, and the recurrent 
lesions showed partial response to neoadjuvant FLOX 
(Fig.  1 middle left). All lesions were resected with clear 
margins, and the two lesions with poorest response to 
chemotherapy remained amenable to sampling, organoid 
culturing and genomics (T2: 3  mm diameter reduction, 
corresponding to 25% tumor shrinkage; T3: 2 mm diam-
eter increase, 11% tumor growth). Both PDOs showed a 
Fig. 1 Clinical history of the patient. One increment in the timeline ruler corresponds to five weeks, and numbers indicate months starting from 
the MRI before neoadjuvant systemic treatment to surgical interventions. Left column shows MRIs (transverse plane) before and after neoadjuvant 
combination chemotherapy for all three surgeries, and bar graphs indicate radiologic response measurements of individual lesions (T1–T5 are 
sampled lesions, Tx are non-sampled lesions) as the percent difference in diameter (% ΔØ) and as the absolute size difference in mm (Δmm). 
Columns to the right indicate (from left) chemotherapy (number of cycles and duration), resection of liver metastases, tissue sampling from the 
indicated liver segment (Roman numeral), immunohistochemistry of diagnostic markers in PDOs and one tissue sample. Scale bar = 50 µm. FLOX 
5-fluorouracil, leucovorin, and oxaliplatin, FLIRI 5-fluorouracil, leucovorin, and irinotecan, PDO patient-derived organoid, LM liver metastasis, NED No 
evidence of disease, H&E hematoxylin and eosin
(See figure on next page.)
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more undifferentiated phenotype compared to the PDO 
from the first resection, with small or absent lumens, and 
disorganized epithelial cell layers with ECAD, CDX2 and 
CK20 expression (Fig. 1 middle right).
Ten weeks after re-resection, one previously unde-
tected metastatic lesion and three new lesions were 
seen on follow-up MRI. Four cycles of neoadjuvant 
treatment with 5-FU, leucovorin and irinotecan (FLIRI) 
resulted in heterogeneous responses among the lesions 
(Fig.  1 bottom left). Two of the new lesions were 
resected and submitted for organoid culturing and 
genomics (T4: no diameter change of the 6  mm large 
tumor; T5: 1 mm diameter reduction corresponding to 
9% tumor shrinkage), and the two other lesions were 
treated with radiofrequency ablation. Similar to PDOs 
from the second liver surgery (T2 and T3), PDOs from 
T4 and T5 exhibited an undifferentiated morphology, 
but with a slightly stronger CK20 and CDX2 expression 
(Fig.  1 bottom right). For reference, the correspond-
ing tissue sample from the T5 lesion was stained for 
the same diagnostic markers, showing that the PDO 
retained the undifferentiated phenotype and expression 
patterns of the tumor.
Spatio‑temporal co‑clinical evaluation of standard 
chemotherapies
All PDOs were screened with a customized medium-
throughput drug library incorporating 33 single agents 
and three 5-FU-based drug combinations with Leuco-
vorin (FLV), Oxaliplatin (FLOX), and SN-38 (FLIRI) 
(Fig.  2A, B). Co-clinical evaluation of FLOX showed 
that the PDO from the first resection reflected the 
strong clinical response in the corresponding T1 lesion 
(Fig.  1 upper left and Fig.  2B). The GRDSS in the T1 
PDO indicated a particularly strong sensitivity to 5-FU, 
also in comparison to our reference dataset of 46 PDOs 
from 23 patients with resected CRC liver metastases 
[9] (Fig.  2A), suggesting that the clinical response was 
primarily driven by this agent. Sensitivity to 5-FU was 
much lower in the two PDOs from the second resection, 
and sensitivity to oxaliplatin was largely unchanged, 
consistent with the weaker clinical responses to FLOX 
in the corresponding lesions (T2 and T3). Notably, het-
erogeneous sensitivity to combination therapies with 
FLV and FLOX between T2 and T3 PDOs did not cor-
respond to the relative radiological responses of the 
corresponding lesions (Fig.  2B), potentially related to 
the poor clinical response of both lesions. T4 and T5 
PDOs from the third resection showed higher sensi-
tivity to oxaliplatin and lower sensitivity to FLIRI than 
PDOs from previous resections, possibly associated 
with a different selection pressure after the change in 
treatment from FLOX to FLIRI in the third neoadjuvant 
setting. 5-FU showed heterogeneous activity between 
T4 and T5 PDOs, not consistent with the poor clini-
cal responses to FLIRI in corresponding lesions, or the 
small difference in ex vivo sensitivity to FLIRI between 
the PDOs.
Across all PDOs and the reference PDO dataset, gene 
expression signatures of response and resistance to 
5-FU [31], analyzed as GSVA scores, were significantly 
correlated to the measured 5-FU sensitivity (Fig. 2C).
Increased sensitivity to SMAC mimetic LCL161 in recurrent 
lesions
Low sensitivity to EGFR inhibitors was confirmed in 
these KRAS mutated PDOs, both relative to other anti-
cancer agents and relative to RAS wild-type PDOs in 
the reference dataset (Fig. 2A and D). The highest mean 
sensitivity score in the five PDOs across the complete 
tested panel of single agents was found for the SMAC 
mimetic LCL161 (Fig. 2A). However, most of the drugs 
showed intra-patient heterogeneity and differential 
activities among the five PDOs. Largest difference in 
sensitivity was found for LCL161, showing higher activ-
ity in PDOs from the second and third resections, with 
5.8 and 4.4-fold higher GRDSS compared to T1 PDOs, 
respectively, and far lower  IC50 than the maximum 
plasma concentration of LCL161 [36] (Fig.  3A). The 
(See figure on next page.)
Fig. 2 Drug sensitivity analyses of a medium throughput drug library. (A, upper panel) GRDSS of 33 drugs in T1–T5 (colored dots) as compared to 
the reference PDO lines (grey dots, n = 46). (A, lower panel) Mean GRDSS of 33 drugs in T1–T5 centered to the mean of the entire dataset (n = 51). 
The grey line within the bars indicates standard deviation of the respective drug’s GRDSS for T1–T5 lesions. B Drug activities of 5-FU, oxaliplatin, SN-38 
(active metabolite of irinotecan) as single agents and combination therapies in T1-T5 PDOs. C Scatter plots of 5-FU drug sensitivity scores (growth 
rate adjusted) and GSVA scores of signatures of 5-FU sensitivity and resistance in PDOs from this patient (colored as indicated) and a reference 
PDO dataset (grey). D EGFR inhibitor activities and their association with RAS/RAF mutation status analyzed in 23 mutated and 28 wild type PDOs. 
GRDSS—Growth adjusted drug sensitivity scores, 5-FU 5-fluorouracil, FLV 5-FU + 10 μM leucovorin, FLOX 5-FU and oxaliplatin at 1:1 ratios + 10 μM 
leucovorin, FLIRI 5-FU and SN-38 at 100:1 ratios + 10 μM leucovorin, GSVA—gene set variation analysis
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molecular hallmark of LCL161 activity is degradation 
of the targets c-IAP1, c-IAP2 and XIAP [19, 36, 37], 
and this was evident in post-treatment PDOs of all five 
lesions (Fig.  3B). Protein expression of XIAP and Sur-
vivin was highest in the resistant T1 PDOs, both after 
treatment with DMSO (control) and LCL161. In con-
trast, c-IAP1, c-IAP2 and XIAP were almost completely 
degraded after LCL161 treatment in the sensitive T2-T5 
PDOs (Fig.  3B). Furthermore, treatment with LCL161 
resulted in induction of apoptosis in a concentration- 
and time-dependent manner in the sensitive T3 PDOs, 
but not in the T1 PDOs, as indicated by increased 
PARP-, Caspase 7-, Caspase 8 and Caspase 3 activation 
(Fig. 3C).
Important mediators of TNF alpha signaling such 
as TNF, TNFRSF12A, three RIPK gene family mem-
bers and genes encoding other apoptosis regulators 
such as CASP9, BAK1 and BIRC3 had expression lev-
els positively correlated with LCL161 sensitivity across 
the T1-T5 and reference PDO dataset collectively 
(Fig.  3D). Strongest correlation with LCL161 activ-
ity was found for RIPK1 (Pearson r = 0.6, p < 0.0001), 
which also showed significant correlation among the 
T1-T5 PDOs separately (Pearson r = 0.92, p = 0.03). 
Furthermore, GSVA scores of the “Hallmark” gene 
set collection showed enrichment with the “TNFA 
signaling via NFKB” signature in all five PDOs from 
this patient, compared to the reference PDO dataset 
(Fig.  3E). This signature was also significantly asso-
ciated with the gene sets of epithelial-mesenchymal 
transition, TGFβ, upregulated KRAS, inflammation, 
and apoptosis, both in liver metastasis tissue samples 
[9] and corresponding PDOs, suggesting molecular 
interactions of the pathways (Fig. 3F). Notably, LCL161 
sensitivity in PDOs was significantly correlated with 
GSVA scores of almost all of these gene sets (Fig. 3E), 
and most strongly with inflammatory response (Par-
sons’s r = 0.44, p = 0.0012).
Discussion
Stratification of cancer patients according to molecu-
lar and functional tumor characteristics can improve 
treatment outcomes [17]. Here, we employed a multi-
disciplinary approach to analyze spatio-temporal phar-
macogenomic heterogeneity in a patient with recurrent, 
KRAS mutated liver metastases from rectal cancer. 
Ex  vivo co-clinical analyses of standard, neoadjuvant 
combination chemotherapies at three consecutive liver 
resections modeled the dynamics of clinical treatment 
responses, including indications of acquired resistance to 
FLOX. Furthermore, a switch in systemic treatment from 
FLOX to FLIRI corresponded to a higher ex vivo activity 
of oxaliplatin, indicating re-sensitization.
KRAS mutation in a microsatellite stable background 
and an undifferentiated histopathology are parameters 
associated with an unfavorable patient prognosis and 
limited systemic treatment options after development 
of resistance to standard therapies [18]. This case report 
indicated vulnerability to the experimental SMAC 
mimetic LCL161, showing higher drug activity in the 
recurrent liver metastases. LCL161 sensitivity patterns 
were supported by mechanistic analyses of the drug 
targets and TNF-α signaling, indicating target engage-
ment and a potential for response prediction by RIPK1 
gene expression levels, consistent with previously pub-
lished clinical data in breast cancer [38]. Furthermore, 
IAP inhibitors can induce anti-tumor immunity [39, 
40], and the strong inflammatory response in T1-T5 
PDOs supports potency of a combination treatment 
of LCL161 and immune modulatory drugs. Combina-
tion with anti-PD1 therapy is currently being tested in 
a phase I study in patients with CRC (ClinicalTrials.gov 
Identifier: NCT02890069).
In conclusion, this case report supports that ex  vivo 
pharmacotranscriptomics can model longitudinal 
treatment efficacy in metastatic CRC. It also supports 
further investigation of LCL161 as an anticancer agent, 
Fig. 3 Anticancer activities of LCL161. A LCL161 GRDSS and  IC50 distribution in T1-T5 PDOs. Reference PDOs are indicated in grey. B Protein 
expression of IAPs analyzed with Western blotting after treatment with DMSO (−) and 200 nM LCL161 ( +) for 48 h. C Time dependent effects 
of 200 nM (lo) and 2000 nM (hi) LCL161 on PARP cleavage, inhibition of XIAP and c-IAP1, Caspase- 8, 7 and 3 cleavage in LCL161-resistant T1 and 
sensitive T3 PDOs. (D, upper panel) Pearson correlation of significantly associating genes of RIP kinase family, gene members of the TNF signaling 
and other apoptosis regulators with GRDSS of LCL161. (D, lower panel) Scatter plot of RIPK1 gene expression versus LCL161 drug activity in PDOs. E. 
Enriched “Hallmark” gene sets in T1–T5 PDOs (colored) as compared to the reference PDO lines n = 46 (grey). F Scatter plot of Pearson’s correlation 
coefficients (r) between the “TNFA signaling via NFKB” gene set and remaining 49 “Hallmark” gene sets analyzed in 51 PDO lineages (vertical axis) 
and 30 liver metastasis tissue samples (horizontal axis). Highlighted in red are the gene sets that are enriched in T1-T5 PDOs and significantly 
associated with LCL161 drug activity. GRDSS Growth adjusted drug sensitivity scores, IC50 the half maximal inhibitory concentration, Cmax the 
maximum serum concentration of a drug, kDa kilodalton, GSVA gene set variation analysis
(See figure on next page.)
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although clinical translation of results from this case 
report was not possible due to the lack of ongoing stud-
ies of IAP inhibitors in Norway.
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